Harmony Biosciences Holdings, Inc. HRMY
Institutional shares held
45.2 Million
108K
calls
49.2K
puts
Total value of holdings
$1.62B
$3.86M
calls
$1.76M
puts
Market Cap
$2.05B
59,161,400
Shares Out.
Institutional ownership
76.43%
# of Institutions
243
We take great care to ensure that the data presented and summarized in this overview for Harmony Biosciences Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HRMY
View all-
Valor Management LLC Chicago, IL11.2MShares$389 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$202 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$120 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$90.4 Million15.24% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.93MShares$66.9 Million0.18% of portfolio
-
State Street Corp Boston, MA1.24MShares$43 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.05MShares$36.5 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO856KShares$29.7 Million0.02% of portfolio
-
Morgan Stanley New York, NY851KShares$29.5 Million0.0% of portfolio
-
Lsv Asset Management Chicago, IL772KShares$26.8 Million0.07% of portfolio
Latest Institutional Activity in HRMY
Top Purchases
Top Sells
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Insider Transactions at HRMY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2024
|
Valor Iv Pharma Holdings, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
600,000
-8.31%
|
$18,000,000
$30.3 P/Share
|
|
Nov 05
2024
|
Marshman Fund Trust Ii > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
600,000
-9.02%
|
$18,000,000
$30.3 P/Share
|
|
Nov 01
2024
|
Valor Iv Pharma Holdings, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,000,000
-35.66%
|
$120,000,000
$30.3 P/Share
|
|
Nov 01
2024
|
Marshman Fund Trust Ii > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,000,000
-37.55%
|
$120,000,000
$30.3 P/Share
|
|
Oct 29
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
21,496
-100.0%
|
$859,840
$40.47 P/Share
|
|
Oct 29
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,496
+50.0%
|
$515,904
$24.0 P/Share
|
|
Oct 03
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
36,357
-99.03%
|
$1,272,495
$35.33 P/Share
|
|
Oct 01
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
400
-100.0%
|
$16,000
$40.19 P/Share
|
|
Oct 01
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+50.0%
|
$9,600
$24.0 P/Share
|
|
Sep 30
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,643
-39.41%
|
$945,720
$40.0 P/Share
|
|
Sep 30
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
95,846
+50.0%
|
$1,150,152
$12.0 P/Share
|
|
Sep 30
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
32,052
-53.42%
|
$1,282,080
$40.0 P/Share
|
|
Sep 30
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+50.0%
|
-
|
|
Sep 30
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
35,846
-100.0%
|
$1,433,840
$40.03 P/Share
|
|
Sep 27
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
200
-100.0%
|
$8,000
$40.05 P/Share
|
|
Sep 27
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+50.0%
|
$4,800
$24.0 P/Share
|
|
Mar 29
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,013
-53.42%
|
$264,429
$33.58 P/Share
|
|
Mar 29
2024
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 15
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,979
-100.0%
|
$383,328
$32.0 P/Share
|
|
Mar 15
2024
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,979
+50.0%
|
$95,832
$8.22 P/Share
|
Last 12 Months Summary
Buy / Acquisition
205K
Shares
From
2
Insiders
| Exercise of conversion of derivative security | 205K shares |
|---|
Sell / Disposition
9.37M
Shares
From
5
Insiders
| Payment of exercise price or tax liability | 63.7K shares |
|---|---|
| Open market or private sale | 9.31M shares |